Wunderlich Capital Managemnt Lowers stake in Amgen (AMGN)

Amgen (AMGN) : Wunderlich Capital Managemnt reduced its stake in Amgen by 0.41% during the most recent quarter end. The investment management company now holds a total of 10,725 shares of Amgen which is valued at $1.6 Million after selling 44 shares in Amgen , the firm said in a disclosure report filed with the SEC on May 11, 2016.Amgen makes up approximately 1.41% of Wunderlich Capital Managemnt’s portfolio.

Other Hedge Funds, Including , Canandaigua National Bank Trust Co boosted its stake in AMGN in the latest quarter, The investment management firm added 695 additional shares and now holds a total of 7,135 shares of Amgen which is valued at $1.1 Million. Amgen makes up approx 0.32% of Canandaigua National Bank Trust Co’s portfolio.Diam Ltd. reduced its stake in AMGN by selling 9,309 shares or 2.9% in the most recent quarter. The Hedge Fund company now holds 311,361 shares of AMGN which is valued at $47.7 Million. Amgen makes up approx 0.69% of Diam Ltd.’s portfolio.Capital Advisors Incok boosted its stake in AMGN in the latest quarter, The investment management firm added 1,936 additional shares and now holds a total of 69,877 shares of Amgen which is valued at $10.7 Million. Amgen makes up approx 1.73% of Capital Advisors Incok’s portfolio.St. Johns Investment Management Company boosted its stake in AMGN in the latest quarter, The investment management firm added 10 additional shares and now holds a total of 8,058 shares of Amgen which is valued at $1.3 Million. Amgen makes up approx 1.13% of St. Johns Investment Management Company’s portfolio.

Amgen opened for trading at $152.35 and hit $153.86 on the upside on Monday, eventually ending the session at $153.27, with a gain of 0.60% or 0.92 points. The heightened volatility saw the trading volume jump to 24,15,093 shares. Company has a market cap of $115,139 M.

On the company’s financial health, Amgen reported $2.90 EPS for the quarter, beating the analyst consensus estimate by $ 0.29 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $2.61. The company had revenue of $5527.00 million for the quarter, compared to analysts expectations of $5321.84 million. The company’s revenue was up 9.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.48 EPS.

Many Wall Street Analysts have commented on Amgen. Citigroup Initiated Amgen on Feb 25, 2016 to “Neutral”, Price Target of the shares are set at $165.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Leave a Reply

Amgen - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amgen. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.